Business Wire

CA-WILSON-SONSINI

9.11.2022 14:01:38 CET | Business Wire | Press release

Share
Jindrich Kloub Joins Wilson Sonsini’s Antitrust and Competition Team in Brussels

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jindrich Kloub has joined the firm’s antitrust and competition department as a partner in the Brussels office. Kloub’s more than 10 years of service at the European Commission’s Directorate-General for Competition and his most recent Hong Kong Competition Commission (HKCC) role illustrate the range of his enforcement agency experience and connections. His addition fortifies Wilson Sonsini’s acclaimed antitrust and competition practice in the United States and Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221109005164/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Jindrich Kloub, Partner, Wilson Sonsini (Photo: Business Wire)

Most recently, Kloub was executive director of operations at the HKCC, where he was responsible for all antitrust enforcement since 2017. In this role, he oversaw numerous precedent-setting investigations, including one that led to the HKCC’s first abuse of dominance enforcement action, as well as its first enforcement outcomes involving resale price maintenance, digital markets, leniency, settlements, commitments, director disqualifications and compliance remedies.

Kloub also has substantial international antitrust and competition policy experience. For example, in addition to leading the development of a fining methodology and cooperation and commitments policies, he oversaw major revisions to the HKCC’s leniency guidelines, which have been described within the private antitrust and competition bar as a world-class policy.

Before joining the HKCC, Kloub worked as an attorney at the European Commission’s Directorate-General for Competition (DG COMP) for more than a decade. During that time, he conducted numerous international cartel investigations, including major international cartel investigations in the financial services sector involving LIBOR and Forex benchmark rates.

“Because Hong Kong’s competition law was based on EU competition law, Jindrich has worked at two enforcement agencies that are highly engaged in monitoring and enforcing competition and antitrust laws of importance to our clients,” said Doug Clark, managing partner, Wilson Sonsini. “Jindrich’s enforcement and policy experience is the ideal combination to complement our already highly regarded antitrust and competition practice. We’re very excited to welcome him to the firm.”

Kloub’s addition comes just over a year and a half after Wilson Sonsini announced that Brent Snyder was joining the firm’s antitrust and competition practice on March 1, 2021. Snyder also joined the firm from the HKCC, having served as its CEO from 2017 through 2020.

“I’m pleased to be joining Wilson Sonsini’s accomplished competition and antitrust team, and excited about my role in helping the firm continue to expand its impressive, global practice and presence in Europe,” said Kloub. “This position not only gives me a chance to apply my enforcement and policy experience to help clients manage matters in both Europe and the U.S., but it’s also an exciting opportunity to work with Wilson Sonsini’s impressive range of clients.”

“Jindrich’s addition to our Brussels office further demonstrates Wilson Sonsini’s growing presence and strong brand in Europe – especially within the complex and constantly changing digital regulatory framework that impacts both antitrust and data protection,” said Cedric Burton, managing partner of Wilson Sonsini’s Brussels office. “Our growing team will be able to offer a new level of service and expertise on the ground to our clients within the European Union.”

Kloub earned his Master of Laws from Charles University School of Law in Prague in 2003 and his LL.M. from Columbia Law School in 2009. He has served as a visiting professor of competition law at Lille’s Catholic University for more than a decade, spoken widely at international conferences, and written numerous articles on competition law.

About Wilson Sonsini Goodrich & Rosati

For more than 60 years, Wilson Sonsini’s services and legal disciplines have focused on serving the principal challenges faced by the management and boards of directors of business enterprises. The firm is nationally recognized as a leading provider to growing and established clients seeking legal counsel to complete sophisticated corporate and technology transactions; manage governance and enterprise-scale matters; assist with intellectual property development, protection, and IP-driven transactions; represent them in contested disputes; and/or advise them on antitrust or other regulatory matters. With deep roots in Silicon Valley, Wilson Sonsini has 19 offices in technology and business hubs worldwide. For more information, please visit www.wsgr.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005164/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release

IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million

IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release

IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p

HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release

HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha

Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release

Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char

DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release

Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye